OptimizeRx Corp. (NASDAQ:OPRX) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $11.57.

OPRX has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, August 25th. Citigroup restated a “market outperform” rating on shares of OptimizeRx in a research report on Tuesday, October 27th. Stifel Nicolaus set a $12.00 price target on OptimizeRx in a research note on Thursday, August 13th. UBS Group set a $11.00 price target on OptimizeRx in a report on Friday, August 14th. Finally, Citizens Jmp upped their price target on OptimizeRx from $9.00 to $11.00 and gave the stock a “market outperform” rating in a report on Friday, August 14th.

OptimizeRx Stock Performance

Shares of NASDAQ OPRX opened at $8.76 on Monday. The company’s fifty day moving average price is $8.35 and its 200 day moving average price is $7.28. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $18.37. The company has a market capitalization of $165.04 million, a PE ratio of 38.09 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.58 and a current ratio of 5.58.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The company had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.20 million. On average, research analysts predict that OptimizeRx will post 0.49 earnings per share for the current year.

Institutional Trading of OptimizeRx

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Corient Private Wealth LP acquired a new position in shares of OptimizeRx during the 2nd quarter worth approximately $77,000. AWM Investment Company Inc. purchased a new position in shares of OptimizeRx during the 2nd quarter valued at approximately $1,375,000. Bank of New York Mellon Corp purchased a new position in shares of OptimizeRx during the 2nd quarter valued at approximately $370,000. Segall Bryant & Hamill LLC acquired a new stake in OptimizeRx in the 1st quarter valued at $1,185,000. Finally, Quantinno Capital Management LP grew its stake in OptimizeRx by 180.1% in the 1st quarter. Quantinno Capital Management LP now owns 49,022 shares of the company’s stock valued at $308,000 after acquiring an additional 31,518 shares during the period. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey.

The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.

OptimizeRx was founded in 2006 and has primarily served the U.S.